The Pharma Data

MARCH 29, 2022

(NYSE: PFE) today announced positive top-line results from a second Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). Participants received etrasimod 2 mg or placebo once-daily.

Trials 52

Trials Small Molecule Biosimilars Disease 52

The Pharma Data

JANUARY 26, 2021

The PRESECO study aims to determine the efficacy of Avigan as an early treatment for COVID-19 patients with mild-to-moderate symptoms, with the goal of alleviating symptoms and preventing disease progression before the infection requires hospitalizations or other intensive interventions. Dr. Reddy’s operates in markets across the globe.

Hospitals 40

Hospitals Laboratories Pharmaceuticals Production 40

The Pharma Data

SEPTEMBER 10, 2020

“Meaningful innovation in cancer care requires building upon our understanding of tumor biology, leveraging cutting-edge research, and applying the knowledge we gain into new treatments that address and prevent resistance,” said Chris Boshoff, M.D., Chief Development Officer, Oncology, Pfizer Global Product Development. “We Solomon B. . .

Therapies 52

Therapies Production Clinical Trials Trials 52

The Pharma Data

FEBRUARY 8, 2021

IBRANCE is indicated for the treatment of adult patients with HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or in men; or with fulvestrant in patients with disease progression following endocrine therapy. 2,3 In the U.S.,

Clinical Trials 52

Clinical Trials Treatment Therapies Production 52

The Pharma Data

JULY 21, 2021

Pharmaceuticals Division sales decline 3%; sales grow 4% in the second quarter, following a first-quarter decrease of 9%; newly launched medicines (+30%) compensate for the continued impact from biosimilars. The ongoing impact from biosimilars, particularly in the US, resulted in a sales decrease of CHF 2.8 Outlook confirmed for 2021.

Biosimilars 52

Biosimilars Pharmaceuticals FDA Disease 52

The Pharma Data

FEBRUARY 8, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

FEBRUARY 4, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

JULY 15, 2021

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. For more than 170 years, we have worked to make a difference for all who rely on us. About the UK Biobank. Source link: [link].

Disease 52

Disease Biosimilars Government Treatment 52

The Pharma Data

JULY 8, 2021

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. For more than 170 years, we have worked to make a difference for all who rely on us.

Disease 52

Disease Government Clinical Trials Research 52

The Pharma Data

APRIL 27, 2021

at CER driven by growth drivers Dupixent ® and Vaccines. Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere. Vaccines delivered growth in its core segments. reflecting lower treatment compliance during the COVID-19 pandemic. Q1 2021 sales increase of 2.4% In the U.S.

Vaccine 52

Vaccine Production FDA FDA Approval 52

FDA Law Blog: Biosimilars

JUNE 2, 2023

Kirschenbaum — Last Friday, May 26, CMS published in the Federal Register an assortment of proposals to change the regulations governing the Medicaid Drug Rebate Program. Vaccine”: Because vaccines are excluded from the MDRP, CMS proposes to define them solely for purposes of the MDRP.

Drugs 59

Drugs Regulations Government Vaccine 59

The Pharma Data

APRIL 7, 2023

BRAFTOVI + MEKTOVI is currently approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. “For more than a decade, Pfizer Oncology has been at the forefront of bringing biomarker-driven treatment options to patients with cancer.

FDA 40

FDA FDA Approval Small Molecule Drugs 40

The Pharma Data

OCTOBER 27, 2020

MP0420 and MP0423 are potential medicines with a unique approach for both the prevention and treatment of COVID-19, with the possibility to manufacture at scale, easy administration and with the potential to bypass cold storage. During the clinical development stage, Molecular Partners will provide clinical supply.

Therapies 52

Therapies Virus Treatment Clinical Trials 52

Agency IQ

SEPTEMBER 29, 2023

What we expect to be talking about in October: Government shutdown: The odds of a government shutdown happening in October are, we think, rather high absent a last-minute breakthrough in Congressional negotiations. Of note: A government shutdown would likely delay or cancel some of the events listed below.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

MAY 4, 2021

to $3.65, Primarily Reflecting Updates to Anticipated Contributions from BNT162b2 Partially Offset by Additional R&D Expenses for Vaccines to Protect Against COVID-19 as Well as Other mRNA-Based Development Programs and COVID-19 Antivirals. Raises Full-Year 2021 Guidance (3) for Revenues to a Range of $70.5 Adjusted Income (2).

Vaccine 40

Vaccine Production FDA Clinical Trials 40

The Pharma Data

AUGUST 21, 2020

Top Russian doctor quits over questionable ethics that rushed through coronavirus vaccine approval. Professor Alexander Chuchalin has quit the Russian Health Ministry’s ethics council due to the quick approval process for the country’s coronavirus vaccine. China approves its first biosimilar of Roche’s Herceptin in HER2+ cancers.

Biosimilars 52

Biosimilars Pharmacy Vaccine Pharmaceuticals 52

The Pharma Data

MAY 14, 2021

. Biogen’s experimental eye treatment fails to meet study goal ( Reuters ) ( Endpoints ). Fully vaccinated people can shed their masks in most places – CDC ( Reuters ) ( STAT ). US diplomats: Send vaccine overseas now or China, Russia will win out ( Politico ). Medtech.

FDA 52

FDA Therapies Vaccine Biosimilars 52

The Pharma Data

MAY 3, 2021

Feds rethink vaccination strategy as slowing demand reveals stark divide ( Politico ). US to launch trade talks on COVID-19 vaccine distribution ( AP ) ( CNBC ). Next Generation of Covid-19 Vaccines Could Be Pill or Spray ( WSJ ). Government, Regulatory & Legal.

Vaccine 52

Vaccine Biosimilars FDA Regulations 52

Drug Hunter

APRIL 24, 2023

The healthcare specific portion of the act is estimated to lower the government deficit by $237 billion to over $265 billion over the next decade based on CBO and senate estimates. Due to elimination of out of pocket patient costs for vaccines covered by Medicare/Medicaid access to adult vaccines will improve.

Small Molecule 130

Small Molecule Biosimilars Drugs Vaccine 130

The Pharma Data

MAY 17, 2021

. Covid-19 Drugmakers Take On Your Favorite TV Shows to Tackle Vaccine Hesitancy ( WSJ ). Incyte’s vitiligo treatment meets main goal in late-stage trial ( Reuters ). US Supreme Court denies Sandoz petition to review biosimilar Erelzi case ( Press ). Now they fear an increase.

Trials 52

Trials Vaccine FDA Biosimilars 52